perhexiline has been researched along with Myocardial Ischemia in 12 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 6.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "Rationale for treatment with perhexiline included myocardial ischemia in 88% and severe systolic heart failure in 38%." | 3.83 | Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit. ( Choi, BY; Chong, CR; Horowitz, JD; Phuong, H; Raman, B, 2016) |
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 2.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "In a prospective study, steady-state plasma concentrations of (+) and (-)-perhexiline were quantified in 10 CYP2D6 genotyped patients following dosing with 100 mg/day rac-perhexiline maleate, and following a subsequent dosage increase to 150 or 200 mg/day." | 1.34 | Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. ( Coller, JK; Davies, BJ; Herbert, MK; Horowitz, JD; Inglis, SC; James, HM; Milne, RW; Morris, RG; Sallustio, BC; Somogyi, AA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ceccarelli, SM | 1 |
| Chomienne, O | 1 |
| Gubler, M | 1 |
| Arduini, A | 1 |
| Phuong, H | 1 |
| Choi, BY | 1 |
| Chong, CR | 1 |
| Raman, B | 1 |
| Horowitz, JD | 6 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Noble, MI | 1 |
| Drake-Holland, AJ | 1 |
| Bansal, M | 1 |
| Chan, J | 1 |
| Leano, R | 1 |
| Pillans, P | 1 |
| Horowitz, J | 3 |
| Marwick, TH | 1 |
| Chirkov, YY | 1 |
| Kennedy, JA | 2 |
| Sverdlov, AL | 1 |
| Lee, L | 2 |
| Frenneaux, M | 2 |
| Campbell, R | 1 |
| Scheuermann-Freestone, M | 1 |
| Taylor, R | 1 |
| Gunaruwan, P | 1 |
| Williams, L | 1 |
| Ashrafian, H | 2 |
| Fraser, AG | 1 |
| Clarke, K | 1 |
| Davies, BJ | 2 |
| Coller, JK | 2 |
| James, HM | 2 |
| Somogyi, AA | 2 |
| Sallustio, BC | 2 |
| Inglis, SC | 1 |
| Herbert, MK | 1 |
| Morris, RG | 1 |
| Milne, RW | 1 |
| Frenneaux, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery[NCT00845364] | Phase 2/Phase 3 | 290 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy[NCT00989508] | Phase 2/Phase 3 | 220 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for perhexiline and Myocardial Ischemia
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricula | 2010 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Com | 2004 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
2 trials available for perhexiline and Myocardial Ischemia
| Article | Year |
|---|---|
Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction.
Topics: Aged; Cardiotonic Agents; Cardiovascular Agents; Dobutamine; Echocardiography; Exercise Test; Female | 2010 |
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Echocardiography, Stress; Fatty Acids; Female; Glucose | 2005 |
6 other studies available for perhexiline and Myocardial Ischemia
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; E | 2011 |
Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug Monitoring; Female; Follow-Up Studies; Heart Fa | 2016 |
Lack of effect of perhexiline in ischaemic heart failure.
Topics: Cardiovascular Agents; Humans; Myocardial Ischemia; Perhexiline; Treatment Failure | 2010 |
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Topics: Aged; Aged, 80 and over; Alleles; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Gene Frequency; Ge | 2006 |
Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Topics: Biological Availability; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Genotype; Humans; Metabolic | 2007 |
Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart.
Topics: Amiodarone; Animals; Carnitine O-Palmitoyltransferase; Dose-Response Relationship, Drug; In Vitro Te | 1998 |